SOPHiA GENETICS (SOPH) Cash & Equivalents (2020 - 2025)

SOPHiA GENETICS (SOPH) has 6 years of Cash & Equivalents data on file, last reported at $70.3 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 12.39% year-over-year to $70.3 million; the trailing twelve-month figure through Dec 2025 stood at $70.3 million (down 12.39% YoY), and the FY2025 full-year result was $70.3 million, down 12.39% from the prior year.
• Cash & Equivalents fell to $70.3 million in Q4 2025, from $81.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $210.0 million in Q3 2021 to a low of $42.5 million in Q2 2021.
• A 5-year average of $125.9 million and a median of $123.3 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 321.07% in 2022 and tumbled 35.47% in 2024, its largest moves.
• Tracing SOPH's Cash & Equivalents over 5 years: stood at $193.0 million in 2021, then dropped by 16.41% to $161.3 million in 2022, then retreated by 23.59% to $123.3 million in 2023, then plunged by 34.91% to $80.2 million in 2024, then decreased by 12.39% to $70.3 million in 2025.
• Business Quant data shows SOPH's Cash & Equivalents at $70.3 million in Q4 2025, $81.6 million in Q3 2025, and $94.8 million in Q2 2025.